600161 天坛生物
2023/12 -
人民幣(K¥)

变动
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
2018/12
人民幣(K¥)
营业总收入5,180,44221.57%4,112,1563,445,5953,281,8602,931,059
减:营业总成本3,429,76417.99%2,873,2252,366,1262,237,0882,070,492
    其中:营业成本2,550,72117.54%2,157,6871,743,6641,645,7301,548,234
               财务费用(49,525)-14.60%(64,148)(30,304)(22,365)(10,762)
               资产减值损失(2,167)-3.85%(15,146)(917)(1,313)1,019
公允价值变动收益------------
投资收益37,21332.31%12,0001,153213175
    其中:对联营企业和合营企业的投资收益------------
营业利润1,804,99526.04%1,244,9071,104,5371,047,437868,359
利润总额1,798,59826.10%1,241,0181,104,8721,043,448867,929
减:所得税费用289,14030.48%172,204161,796149,195132,033
净利润1,509,45925.30%1,068,814943,077894,254735,897
减:非控股权益399,57023.42%308,802304,070283,160226,417
股东净利润1,109,88925.99%760,012639,007611,094509,479

市场价值指针
每股收益 (元) *0.67026.42%0.4700.5100.4900.490
每股派息 (元) *0.150200.00%0.1000.1000.0600.050
每股净资产 (元) *5.96111.63%5.8643.6023.7683.870
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容